



MPS PHARMAA LIMITED

(FORMERLY ADVIK LABORATORIES LIMITED)

Dated: 29.05.2023

**To,
The Manager (Listing)
BSE Limited
1st Floor, P.J. Towers
Dalal Street, Mumbai – 400001**

Sub: Outcome of the Board Meeting and Submission of Audited Financial Results for the quarter and year ended 31st March, 2023 as required u/r 33 of the SEBI (LODR) Regulations, 2015.

Ref: BSE Scrip Code 531686; ASE Scrip Code- 01636 (ADVIK LABO)

Dear Sir,

This is to inform you that pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Monday, 29th May, 2023 at 05:00 P.M at the corporate office of the company at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi – 110001 and concluded at 06:05 P.M has, inter-alia, transacted the following business:

1. Considered and Approved the Standalone Audited Financial Results of the Company for the quarter and year ended 31st March, 2023.
2. Considered and Approved the Auditor's Report for the Audited Financial Results of the Company for the quarter and year ended 31st March, 2023.
3. Considered and taken on record Statement of Impact of Audit Qualification (for audit report with modified opinion) for the Financial Year ended 31st March, 2023 in 'Annexure 1' of SEBI Circular dated May 27, 2016 bearing Circular reference No. CIR/CFD/CMD/56/2016.
4. Considered and appointed M/s Kundan Agrawal & Associates, Company Secretaries as the Secretarial Auditor of the Company for the F.Y. 2023-2024.
5. Considered and appointed M/s Sanghi & Co., Chartered Accountants as the Internal Auditor of the Company for the F.Y. 2023-2024.

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001

Phones: 011-42424884, 43571040-45, **Fax:** 011-43571047

Regd. Office & Factory: 138. ROZ-KaMeoIndustrial Area, Sohna - 122103 (Distt.Mewat), Haryana

Phones: 0124-2362471 **Email:** info@mpspharmaa.com **Website:** www.mpspharmaa.com



MPS PHARMAA LIMITED

(FORMERLY ADVIK LABORATORIES LIMITED)

6. Considered and appointed M/s Saurabh Upadhyay & Associates, Practising Company Secretary for the purpose of obtaining necessary quarterly/half yearly/yearly certificates as required under SEBI (LODR) Regulations, 2015

Further pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Financial Results for the quarter and year ended 31st March, 2023 alongwith Auditor's Report and the aforesaid Statement of Impact of Audit Qualification for modified opinion in 'Annexure-1' are enclosed herewith for your kind perusal.

Kindly take the aforesaid information in your records.

Thanking you.

Yours Truly,

For MPS Pharmaa Limited

(Formerly Advik Laboratories Limited)

POOJA CHUNI

Digitally signed by POOJA CHUNI
Date: 2023.05.29 18:09:38 +05'30'

Pooja Chuni

Company Secretary

Encl: As above

CC:

The Manager (Listing)

Ahmedabad Stock Exchange Limited

1st Floor, Kamdhenu Complex

Opp. Sahajanand College,

Panjara Pole, Ambawadi, Ahmedabad – 380015

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001

Phones: 011-42424884, 43571040-45, **Fax:** 011-43571047

Regd. Office & Factory: 138. ROZ-KaMeoIndustrial Area, Sohna - 122103 (Distt.Mewat), Haryana

Phones: 0124-2362471 **Email:** info@mpspharmaa.com **Website:** www.mpspharmaa.com

 MPS PHARMAA LIMITED(FORMERLY ADVIK LABORATORIES LIMITED) Regd. Off. :138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103 STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2023 CIN : L74899HR1994PLC038300						
		(Rs in Lacs except EPS)				
Sr No	Particulars	Quarter Ended		Year Ended		
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited)	(Unaudited)	(Audited)	Audited	
	Income from Operation					
1	(a) Net Sales/Revenue from Operations	-	-	-		3.24
	(b) Other Operating Income	-	-	-		-
	(c) Other Income	2.33	-	0.44	2.33	25.82
	Total Income	2.33	-	0.44	2.33	29.06
	Expenses					
2	a) Cost of Materials consumed	4.50		1.54	4.50	1.76
	b) Purchase of Stock-in-trade	-	-	-	-	3.19
	c) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade	-	-	0.17	-	0.17
	d) Employee Benefits Expenses	13.08	12.52	10.94	48.74	42.13
	e) Finance Costs	0.01	0.01	0.02	0.05	0.11
	f) Depreciation and Amortisation expense	3.64	3.68	12.84	14.58	51.36
	g) Other expenses	13.37	10.09	6.33	41.55	23.59
	Total Expenses	34.60	26.30	31.84	109.42	122.31
3	Profit/(Loss) before Exceptional items and tax (1-2)	(32.27)	(26.30)	(31.40)	(107.09)	(93.25)
4	Exceptional Items	-	-	-	-	-
5	Profit/(Loss) before tax (3 + 4)	(32.27)	(26.30)	(31.40)	(107.09)	(93.25)
6	Tax Expense					
	- Current tax	-	-	-	-	-
	- Deferred tax	(0.74)	(0.39)	(37.97)	(2.06)	(43.20)
	- Adjustment for MAT credit of earlier years	-	-	(35.89)	-	(35.89)
	Total Tax Expenses	(0.74)	(0.39)	(73.86)	(2.06)	(79.09)
7	Profit/(Loss) for the period (5-6)	(31.53)	(25.91)	42.46	(105.03)	(14.16)
8	Other Comprehensive Income (OCI)					
	Items that will not be reclassified to Profit & Loss Account	0.78	0.43	1.40	2.06	1.71
9	Deferred Tax on OCI	(0.54)			(0.54)	
10	Total Comprehensive Income for the period (7+8-9)	(31.29)	(25.48)	43.86	(103.51)	(12.45)
11	Paid-up equity share capital (face value of Rs 10/- per share)	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14
12	Earning per share (EPS) of Rs 10/- each (not annualized)					
	(1) Basic	(0.16)	(0.14)	0.22	(0.55)	(0.07)
	(2) Diluted	(0.16)	(0.14)	0.22	(0.55)	(0.07)
13	Reserves excluding Revaluation Reserves(Reserves as per Balance sheet of Previous Accounting Year)				(1,632.02)	(1,528.50)

NOTES:-

1	The above Financial Results for the quarter & year ended March 31, 2023 has been reviewed by the Audit Committee and thereafter approved by the Board of Directors & taken on record at its meeting held on May 29, 2023. The Statutory Auditors have carried out the audit for the year ended 31st March, 2023.
2	The Company operates in a single segment viz pharmaceuticals formulations and the results pertain to a single segment in accordance with IND AS 108-Operating Segment.
3	The amount of Rs. 4.50 lacs shown under 'Cost of material consumed' column for the quarter ended March 31, 2023 is due to expiry of the shelf life of some packing materials.
4	During the previous quarter ending 31st December, 2022, The Registrar of Companies, NCT of Delhi & Haryana has approved the change in name of the Company from "ADVIK LABORATORIES LIMITED" to "MPS PHARMAA LIMITED" with effect from December 13, 2022. Accordingly, the name of the Company stands changed from "ADVIK LABORATORIES LIMITED" to "MPS PHARMAA LIMITED" with effect from December 13, 2022.
5	The company has applied for renewal of its Drug Manufacturing Licences before the term of its expiry with the Food & Drugs Administration (FDA), Panchkula, for manufacturing pharmaceutical and allied products and the management of the company firmly believes that the company would be able to restart its business operations as the company is getting quotes from the prospective buyers & the management is of the opinion that the new deals would be finalized soon. Further, the management of the company is also exploring the market and business opportunities and is putting necessary efforts in this respect so that the operations of the company can be started again.
6	The Figures for the quarter ended March 31, 2023 and March 31, 2022 represents the balancing Figures between the audited figures for the full financial years and the published figures for the 9 months ended December 31, 2022 and December 31, 2021 respectively.



[Handwritten signature]

	Auditor's Observations in Audit Report for the Financial year 2022-23:-
7	a) The company had recorded the cost of investment at the face value of the equity shares issued and had not determines the fair value as required by IND-AS. The shares were not made available for physical verification. Hence we are unable to comment upon the physical existence and express an opinion on the value of investment recorded. b) The Capital work in Progress has been stalled. The physical conditions of these assets under construction require technical evaluation to determine impairments or write offs, if any. However, in view of the management, the suspension is temporary in nature and assets under construction are not obsolete, and the company will be able to resume construction activities in near future and accordingly no provision is required.
8	Our explanation to Auditor's Observation:- a. The company has misplaced/lost the share certificates of the Investment made by it in unquoted equity shares of other companies during the shifting of its records. Hence these share certificates are not physically held by the company. The Company has sent various request letters to the companies in which it has made investments for issue of duplicate share certificates. However, till date the company has not received any reply from these companies. In order to ensure the compliance of IND AS in true letter and spirits, the company is also trying to ascertain the fair market value of its investments. b. In order to expand its business operations, the Company had released some funds to contractors to construct an additional block in the factory. However, for the time being and due to some technical and other reasons, the management had to suspend the said construction activity. But, the management of the company believes that the suspension is temporary in nature and assets under construction are not obsolete, and the company will be able to resume construction activities in near future and accordingly no provision is required. Further company is also receiving its advances back from some vendors due to non execution of deal.
9	There is a delay in payment of Annual Listing Fees for the F.Y. 2021-22 & 2022-23 of the BSE. The management of the company is trying to arrange the necessary funds and believes that all the outstanding dues of BSE shall be cleared soon.
10	Previous year/period figures have been regrouped/arranged, wherever necessary to make them comparable with the current period figure.
11	The aforesaid audited results for the quarter & year ended 31st March, 2023 will be available on the website of the company i.e. www.mpspharma.com

Page 2 of 4



For and on behalf of Board of Directors of
MPS Pharmaa Limited
(Formerly Advik Laboratories Limited)


(Peeyush Kumar Aggarwal)

Chairman
DIN : 0090423

Place: New Delhi
Date 29.05.2023




Statement of Assets & Liabilities

(Rs. In lacs)

	Particulars	As at 31.03.23 (Audited)	As at 31.03.22 (Audited)
A.	ASSETS		
1	Non Current Assets		
	Property Plant & Equipment	414.42	417.27
	Capital Work in progress	340.05	342.05
	Other Intangible Assets	-	-
	Non Current Assets	754.47	759.32
	Non Current Financial Assets		
	Investments	53.80	53.80
	Total-Non current assets	808.27	813.12
2	Current Assets		
	Inventories	50.36	54.86
	Current Financial Assets		
	Trade receivables	2.59	3.46
	Cash & cash equivalents	0.73	1.37
	Loans and advances	156.02	142.79
	Other current assets	0.66	0.39
	Total Current Assets	210.36	202.87
	TOTAL ASSETS	1,018.63	1,015.99
B.	EQUITY & LIABILITIES		
1	EQUITY		
	Equity Share Capital	1,911.14	1,911.14
	Other Equity	(1,632.02)	(1,528.50)
	Total Equity	279.12	382.64
2	LIABILITIES		
	Non-Current Liabilities		
	Non-Current Financial Liabilities	-	-
	Other Financial Liabilities	-	-
	Long Term Provisions	13.58	14.60
	Deferred tax liabilities	9.07	10.59
	Total-Non Current Liabilities	22.65	25.19
	Current Liabilities		
	Current Financial Liabilities		
	Borrowings	676.45	580.75
	Trade payables	19.90	12.22
	Other current financial liabilities	20.51	15.19
	Total Current Financial Liabilities	716.86	608.16
	TOTAL EQUITY & LIABILITIES	1,018.63	1,015.99

For and on behalf of Board of Directors of
MPS Pharmaa Limited
(Formerly Advik Laboratories Limited)



(Peeyush Kumar Aggarwal)

Chairman

DIN :0090423

Place: New Delhi
Date 29.05.2023

Statement of Cash Flows for the year ended 31st March, 2023

(Rs. In lacs)

	Particulars	As at 31.03.23 (Audited)	As at 31.03.22 (Audited)
A.	Cash Flow from operating activities		
	Net profit before tax and extraordinary items	(103.51)	(12.45)
	Add: Adjustment for Depreciation	14.58	51.36
	Deferred Tax	(1.52)	(43.20)
	Interest Received	-	(0.01)
	Finance Cost	0.05	0.11
	Operating profit before working capital changes	(90.40)	(4.19)
	Adjustment for:		
	Increase / (Decrease) in Trade Payables	7.69	2.86
	Increase / (Decrease) in Current Liabilities	4.30	(449.44)
	(Increase) / Decrease in Trade Receivables	0.86	56.00
	(Increase) / Decrease in Loans & Advances	(13.23)	(41.38)
	(Increase) / Decrease in Other Current Assets	(0.27)	0.18
	(Increase) / Decrease in Inventories	4.50	1.93
	Cash generated/(used in) from operations	3.85	(429.85)
	Net Cash generated/(used in) from operating activities	(86.55)	(434.04)
B.	Cash flow from investing activities		
	Proceeds from change in Capital Advances	2.00	47.47
	Purchase of Property, Plant & Equipments	(11.73)	(1.13)
	Proceeds from sale of Investment	-	-
	Interest Received	-	0.01
	Net cash outflow from investing activities	(9.73)	46.35
C.	Cash Flow from financing activities		
	Proceeds from/ (Repayment of) Long Term borrowings	95.70	387.91
	Finance Cost	(0.05)	(0.11)
	Net cash used in financial Activities	95.65	387.80
	Net Increase/ (Decrease) in cash & cash equivalents (A+B+C)	(0.64)	0.11
	Cash & Cash Equivalents (Opening balance)	1.37	1.26
	Cash & Cash Equivalents (Closing balance)	0.73	1.37

For and on behalf of Board of Directors of
MPS Pharmaa Limited
(Formerly Advik Laboratories Limited)



(Peeyush Kumar Aggarwal)
Chairman
DIN : 0090423

Place: New Delhi
Date 29.05.2023

NEMANI GARG AGARWAL & CO.
CHARTERED ACCOUNTANTS
1517, DEVIKA TOWER, 6, NEHRU PLACE,
NEW DELHI- 110 019.

Br.Office: Ch. No.5, Kamadgiri Aptt., Kaushambi, Ghaziabad-201010

Tel.-011-26448022/33;0120-4374727

Email ID: sknemani@sknemani.com, nemani61@gmail.com

Independent Auditors' Report on the Quarterly and Year to Date Financial Results of MPS Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors

MPS Pharma Limited

(Formerly known as Advik Laboratories Limited)

Opinion

We have audited the accompanying Statement of quarterly and year to date financial results of MPS Pharma Limited ("the Company") for the quarter and year ended 31 March 2023 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net loss, other comprehensive income and other financial information for the quarter ended 31 March 2023 and net loss, other comprehensive income and other financial information for the year ended 31 March 2023.

Basis of Qualified Opinion

- a) *The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by Ind AS. The shares were not made available for physical verification. Hence, we are unable to comment upon the physical existence and express an opinion on the value of investment recorded.*
- b) *The Capital work in Progress has been stalled. The physical conditions of these assets under construction require technical evaluation to determine impairments or write offs, if any. However in view of the management the suspension is temporary in nature and assets under construction are not obsolete, and the company will be able to resume construction activities in near future and accordingly no provision is required.*

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and the Rules there under, and we



have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matter.

We draw attention to note no. 5 of Financial Result for the year ended March 2023 regarding no Revenue from Operations during FY 2022.23.

Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the audited financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down under Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

Attention is invited to Note No. 6 to the Statement. As stated therein, the Statement includes the results for the quarter ended 31 March 2023 being the balancing figure between the annual audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us.



For Nemani Garg Agarwal & Co.
(Chartered Accountants)
F.R.No. 010192N

[Handwritten signature]

(J.M. Khandelwal)
Partner
M. No. 074267

UDIN:- 23074267BGWKMS4957

Date: May 29, 2023

Place: New Delhi



ANNEXURE – I

Statement of Impact of Audit Qualifications (for audit report with modified opinion) submitted along with Annual Audited Financial Results - (Standalone and Consolidated separately)

Statement of Impact of Audit Qualifications for the Financial year ended March 31, 2023 [See Regulation 33 / 52 of the SEBI (LODR) (Amendment) Regulations, 2016]

Amount in Lakhs

I	Sl. No	Particulars	Audited Figures (as reported before adjusting for qualification)	Adjusted Figures (audited figures after adjusting for qualifications)
	1	Turnover / Total income	2.33	2.33
	2	Total Expenditure	109.42	109.42
	3	Net Profit / (Loss)(After Tax)	(105.03)	(105.03)
	4	Earnings Per Share	(0.55)	(0.55)
	5	Total Assets	1018.63	1018.63
	6	Total Liabilities	739.51	739.51
	7	Net Worth	279.12	279.12
	8	Any other financial item(s) felt appropriate by the management	--	--
II	Audit Qualification (each audit qualification separately)			
	1	Details of Audit Qualification: a) The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by Ind AS. The shares were not made available for physical verification. Hence, we are unable to comment upon the physical existence and express an opinion on the value of investment recorded. b) The Capital work in Progress has been stalled. The physical conditions of these assets under construction require technical evaluation to determine impairments or write offs, if any. However in view of the management the suspension is temporary in nature and assets under construction are not obsolete, and the company will be able to resume construction activities in near future and accordingly no provision is required.		
	2	Type of Audit Qualification : Qualified / Disclaimer of Opinion / Adverse Opinion: Qualified		
	3	Frequency of Qualification(s) : Whether appeared for first time / repetitive / since how long continuing Repetitive / since 2017-2018		
	4	For Audit Qualification(s) where the impact is quantified by the Auditor, Management's Views: a) The company has misplaced/lost the share certificates of the Investment made by it in unquoted equity shares of other companies during the shifting of its records. Hence these share certificates are not physically held by the company. The Company has sent various request letters to the companies in which it has made investments for issue of duplicate share certificates. However, till date the company has not received any reply from these companies. In order to ensure the compliance of IND AS in true letter and spirits, the company is also trying to ascertain the fair market value of its investments. b) In order to expand its business operations, the Company had released some funds to contractors to construct an additional block in the factory. However, for the time being and due to some technical and other reasons, the management had to suspend the said construction activity. But, the management of the company believes that the suspension is temporary in nature and assets under construction are not obsolete, and the company will be able to resume construction activities in near future and accordingly no provision is required. Further company is also receiving its advances back from some vendors due to non-execution of deal.		

5	For Audit Qualification(s) where the impact is not quantified by the auditor: N.A.	
	(i) Management's estimation on the impact of audit qualification:	
	(ii) If Management is unable to estimate the impact, reasons for the same:	
	(iii) Auditor's comments on (i) or (ii) above	
III Signatories		
	Managing Director	 Peeyush Kumar Aggarwal DIN:00090423
	Chief Financial Officer	 Manoj Kumar Bhatia PAN: AAZPB5897R
	Audit Committee Chairman	 Manoj Kumar Jain DIN : 02573858
	Statutory Auditor	 For M/s. Nemani Garg Aggarwal & Co. Chartered Accountants Firm Registration No.: 010192N  (J.M.Khandelwal) Partner M.No. 074267
Place:	New Delhi	
Date:	29.05.2023	